Tags

Type your tag names separated by a space and hit enter

A systematic review of the antipsychotic properties of cannabidiol in humans.
Schizophr Res. 2015 Mar; 162(1-3):153-61.SR

Abstract

Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. Here we review studies that investigated the antipsychotic properties of CBD in human subjects. Results show the ability of CBD to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration. In addition, CBD may lower the risk for developing psychosis that is related to cannabis use. These effects are possibly mediated by opposite effects of CBD and THC on brain activity patterns in key regions implicated in the pathophysiology of schizophrenia, such as the striatum, hippocampus and prefrontal cortex. The first small-scale clinical studies with CBD treatment of patients with psychotic symptoms further confirm the potential of CBD as an effective, safe and well-tolerated antipsychotic compound, although large randomised clinical trials will be needed before this novel therapy can be introduced into clinical practice.

Authors+Show Affiliations

Institute of Psychiatry, Department of Psychosis Studies, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom.Institute of Psychiatry, Department of Psychosis Studies, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom; Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Electronic address: m.bossong@umcutrecht.nl.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review

Language

eng

PubMed ID

25667194

Citation

Iseger, Tabitha A., and Matthijs G. Bossong. "A Systematic Review of the Antipsychotic Properties of Cannabidiol in Humans." Schizophrenia Research, vol. 162, no. 1-3, 2015, pp. 153-61.
Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162(1-3):153-61.
Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1-3), 153-61. https://doi.org/10.1016/j.schres.2015.01.033
Iseger TA, Bossong MG. A Systematic Review of the Antipsychotic Properties of Cannabidiol in Humans. Schizophr Res. 2015;162(1-3):153-61. PubMed PMID: 25667194.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review of the antipsychotic properties of cannabidiol in humans. AU - Iseger,Tabitha A, AU - Bossong,Matthijs G, Y1 - 2015/02/07/ PY - 2014/10/06/received PY - 2015/01/20/revised PY - 2015/01/21/accepted PY - 2015/2/11/entrez PY - 2015/2/11/pubmed PY - 2016/1/5/medline KW - Antipsychotic KW - Cannabidiol KW - Cannabis KW - Psychosis KW - Schizophrenia SP - 153 EP - 61 JF - Schizophrenia research JO - Schizophr Res VL - 162 IS - 1-3 N2 - Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. Here we review studies that investigated the antipsychotic properties of CBD in human subjects. Results show the ability of CBD to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration. In addition, CBD may lower the risk for developing psychosis that is related to cannabis use. These effects are possibly mediated by opposite effects of CBD and THC on brain activity patterns in key regions implicated in the pathophysiology of schizophrenia, such as the striatum, hippocampus and prefrontal cortex. The first small-scale clinical studies with CBD treatment of patients with psychotic symptoms further confirm the potential of CBD as an effective, safe and well-tolerated antipsychotic compound, although large randomised clinical trials will be needed before this novel therapy can be introduced into clinical practice. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/25667194/A_systematic_review_of_the_antipsychotic_properties_of_cannabidiol_in_humans_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(15)00063-8 DB - PRIME DP - Unbound Medicine ER -